Leadership

Management Team

LAM’s strategic vision is guided by focused research and development leading to the creation of a world class healthcare organization.

We are working and innovating tirelessly to make proven science and technology available to patients and physicians today. Instead of what could be possible one day, we are bringing to market tools that enable the early detection of disease allowing patients to take control early on in the process.

At LAM we take this approach very seriously — the first requirement is evidence-based, proven science.

Our leadership fosters an atmosphere of making a positive difference each day. Management recruits individuals with an action-oriented mindset—no matter the job description, our team members come to the organization with that attitude.  This translates into making advancements available sooner while supporting our physicians and their patients with premier customer service and continuing education about the company’s expanding products and services.

Leadership is made up of passionate and experienced managers with diverse industry backgrounds and knowledge, committed to science and the desire to make a difference in patient lives.

Shu Li, PhD

Chairman & Chief Executive Officer

Read Bio

Dr. Shu Li, is Chairman & CEO of Laboratory for Advanced Medicine, Inc. and the founder and Chairman of J&J Investments Worldwide Ltd., an angel investment firm which founded ventures such as WA Health Center International (merged with NASDAQ: KANG), Cellular BioMedicine Group (NASDAQ: CBMG), Global Health Investments, CAS Health Holdings, Yuge.com and Laboratory for Advanced Medicine, Inc.

Dr. Li was the founder and CEO of Jazz Semiconductor (NASDAQ: JAZ), founder and board member of the China-Japan-US JV Huahong NEC (SEHK: 1347.HK), Senior Vice President of Conexant Systems (NASDAQ: CNXT), Vice President and General Manager, Commercial Spares of Honeywell (NYSE: HON), and also held senior management positions at Motorola and Intel.

Dr. Li is a member of the Committee of 100, a leadership organization of Chinese Americans focused on encouraging constructive relations between the people of the United States and China.

He has been a member of the Advisory Board of the Paul Merage School of Business Administration at the University of California Irvine and was on the faculty of the University of Arizona. He has published extensively in prestigious scientific journals such as IEEE Transaction Automatic Control and holds six US and international patents.

Dr. Li received his PhD in Applied Sciences from Harvard University, his MS in Electrical Engineering and Computer Science from the University of Illinois Urbana-Champaign, and his BS in Electrical Engineering from Huazhong University of Science and Technology.

Richard A. Brand, MBA

Chief Financial Officer

Read Bio

Richard Brand is Chief Financial Officer of Laboratory for Advanced Medicine.

Previously, Mr. Brand served as the Chief Financial Officer of BeyondSpring (NASDAQ: BYSI). He was Chairman and Chief Executive Officer of Point Capital, a consultant of the Whalehaven Group of Funds and a registered representative with Andrews Securities where his responsibilities included acting as dealer manager for Keating Capital. Mr. Brand also served as Managing Director of Caisse des Dépôts Securities and FleetBoston Robertson Stephens.

Mr. Brand was Head of Origination and Managing director of Prospect Capital Management and an Investment Advisor and Personnel of Prospect Energy Corp. At Prospect, he focused on sourcing and screening potential Prospect Energy investments. Mr. Brand was with Prospect Capital Management since October 2004.

Mr. Brand began his career as an Investment Banker at PaineWebber in 1980. As a banker and private equity professional, he structured debt financings for a number of oil and gas companies. He served as the Managing Director of Robertson Stephens, where he served on Bayview Fund, the partners’ investment fund and was a Council Member at Gerson Lehrman Group and Advisory Council Member at Global Capital Service Group. He served as Vice President of Donaldson, Lufkin & Jenrette, where he helped establish the Private Funds Group.

Mr. Brand is a member of the Global Association of Risk Professionals. He is the Series 7 – General Securities Representative and the Series 63 – Uniform Securities Agent State Law Examination Securities Representative. He received his MBA in Finance from University of Chicago and his BA in Economics and English from University of Iowa (Phi Beta Kappa).

Richard Van Etten, MD, PhD

Chief Medical Officer

Read Bio

Dr. Van Etten is Chief Medical Officer for Laboratory for Advanced Medicine. Dr. Van Etten is also the Director of the Chao Family Comprehensive Cancer Center at UCI.

He was previously the Director of the Tufts Cancer Center and Chief of the Tufts Hematology and Oncology Division.

Dr. Van Etten is the recipient of the Zucker Family Research Prize and the Lucille P. Markey Scholar Award. He is also a Carl and Margaret Walter Scholar and has published over 90 published peer reviewed papers.

He is a member of the American Associate for Advancement of Sciences, American Society of Hematology, American Society of Clinical Oncology and the Eastern Cooperative Oncology Group. He is a contributing Editor to UpToDate, and on the editorial board of the Journal of Clinical Oncology.

Dr. Van Etten has board certifications in Hematology and Internal Medicine, is accredited by the American Board of Internal Medicine and is affiliated with the Long Beach Memorial Medical Center, Saddleback Memorial Medical Center and UC Irvine Medical Center.

Dr. Van Etten received his PhD in Biophysics and his MD from Stanford University and his BS in Biology and Mathematics from MIT.

Jinjie Hu, PhD

Chief Regulatory Officer

Read Bio

Dr. Hu is currently the Chief Regulatory Officer for Laboratory for Advanced Medicine. Previously, she was the Lead Review Committee Chair and Senior Regulatory Scientist for In Vitro Diagnostics at the United States Food & Drug Administration (FDA). Dr. Hu was a CBER expert reviewer for applications of IVD devices detecting multiple analytes, and the principle reviewer for the scientific and regulatory review of CMC, pre-clinical and clinical sections for IVD device applications. She has collaborated with CDRH and CDER for reviewing companion diagnostic and combination devices, and Clinical Laboratory Improvement Amendments (CLIA) waiver application reviews.

Dr. Hu has completed the review of manufacturing facilities and processes. She has completed pre-license/pre-approval for manufacturing facility inspections at US and international companies, as well as cGMP post-approval manufacturing quality inspections. Additionally, she served as the FDA IVD expert in WHO Technical Working Group and Product Dossier Assessment for Prequalification of Diagnostics. She also served as Quality Assurance Manager to monitor the review progression of all applications submitted to OBRR products under MUDUFA dateline and to establish standard procedures for managed review processes.

Dr. Hu was a Senior Consultant at Biologics Consulting, and the former Chair of the International Network Committee of FDA Alumni.

She continues to be a World Health Organization (WHO) advisor for the Diagnostic Prequalification Program and has been a speaker for WHO training and workshops.

Dr. Hu received her PhD in Comparative Pathology at the University of California, Davis. She was a postdoctoral Fellow at the NIAID, NIH, Laboratory of Molecular Microbiology.

Advisory Board

Salvador B. Sarabosing Jr., CISA, CRISC, MBA

Partner and Head of Risk Advisory, Blythe Global Advisors

Read Bio

  • Former Senior Manager, Ernst & Young
  • Former Senior Manager, Grant Thornton LLP
  • Former Senior Director, Ingram Micro, Inc.
  • MBA University of Southern California

Richard Van Etten, MD, PhD

Director of UCI Cancer Center

Read Bio

  • Former Director of Tufts Cancer Center
  • Zucker Family Research Price and the Lucille P. Markey Scholar Award
  • Carl and Margaret Walter Scholar
  • Over 90 published peer reviewed papers
  • PhD and MD from Stanford

Hans Keirstead, PhD

CEO, AIVITA Biomedical

Read Bio

  • Founder and Director of Sue and Bill Gross Stem Cell Research Center
  • Former CEO, Ability Biomedical (sold to Bristol Myers Squibb)
  • Former CSO, Caladrius
  • Former CEO, California Stem Cell

Terry Belmont

Chairman of Cellular Biomedicine Group (NASDAQ: CBMG)

Read Bio

  • Verity Health Systems Board of Directors
  • Former CEO, UCI Health
  • CEO of other major health care organizations, including executive leadership in Kaiser Permanente

Edward Nelson, MD

Chief, Division of Hematology/Oncology School of Medicine

Read Bio

  • Associate Professor of Medicine
  • Associate Professor Molecular Biology & Biochemistry
  • University of California Irvine

FDA Hepatology Medical Advisors

Steven-Huy B. Han, MD

UCLA Jonsson Comprehensive Cancer Center

Read Bio

  • Professor of Medicine & Surgery
  • Director, Hepatology Clinical Research Center
  • UCLA Jonsson Comprehensive Cancer Center

Ghassan K. Abou-Alfa, MD, MBA

Memorial Sloan-Kettering Cancer Center

Read Bio

  • Gastrointestinal Oncology Service
  • Memorial Sloan-Kettering Cancer Center

Mindie H. Nguyen, MD

Stanford Cancer Institute

Read Bio

  • Professor of Medicine
  • Division of Gastroenterology and Hepatology
  • Stanford University School of Medicine and
  • Stanford Cancer Institute

Roozbeh Houshyar, MD

UCI Medical Center

Read Bio

  • Diagnostic Radiologist
  • American Board of Radiology, Diagnostic Radiology
  • UCI Medical Center

Stanley Hui, MD

University of California San Francisco

Read Bio

  • Former gastroenterologist Kaiser Permanente
  • University of California San Francisco